Drug
Daclizumab clinical trials
Also written Zinbryta.
- studies test it
- 55
- open now
- 0
- in phase 3
- 10
- first study started
- 1996
How studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
55 studies that test it; most in 2002 (8)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1997 | 2 |
| 1999 | 7 |
| 2000 | 3 |
| 2001 | 5 |
| 2002 | 8 |
| 2003 | 7 |
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 30
- Phase 3
- 10
- Phase 4
- 10
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 39
National Eye Institute (NEI) (8) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Biogen (4) · Hoffmann-La Roche (4) · University of Miami (2) · Johns Hopkins University (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Astellas Pharma Inc (2)
Often tested with
Tested in the same studies.
Mycophenolic Acid (6) · Thymoglobulin (5) · Sirolimus (5) · Alemtuzumab (2) · Tacrolimus (2) · Ganciclovir (2) · Infliximab (2) · Cyclosporine (2)
Studies
Open first, then newest update. How each study uses Daclizumab is read from its arms, and is right about nine times in ten.
Testing it · 55
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal TransplantationCompletedPhase 4University of MiamiNCT00685061Written as Daclizumab
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal TransplantationCompletedPhase 4University of MiamiNCT00681343Written as Daclizumab
- Phase I/II Thymus Transplantation With Immunosuppression #950CompletedPhase 1/2Sumitomo Pharma Switzerland GmbHNCT00579527Written as Daclizumab
- CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal TransplantationCompletedPhase 4EMagnussonNCT00246129Written as Daclizumab
- A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureTerminatedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00001962Written as Daclizumab
- Prevention of Diabetes Progression Trial (PDPT)CompletedPhase 2Indiana University School of MedicineNCT00198146Written as Zenapax
- New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical TrialCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00100178Written as Daclizumab (DZB)
- Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedPhase 3BiogenNCT01797965Written as BIIB019 (Daclizumab)
- Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedPhase 2University of Maryland, BaltimoreNCT00006350Written as daclizumab
- Efficacy and Safety of Daclizumab in Participants With RRMS Switching From NatalizumabTerminatedPhase 3BiogenNCT02881567Written as Daclizumab
- Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedPhase 2BiogenNCT01051349Written as BIIB019 (Daclizumab)
- Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive CrossmatchCompletedPhase 3Johns Hopkins UniversityNCT00275509Written as Daclizumab
- The Use of Daclizumab and Anti-Thymocyte Globulin in Lung TransplantationCompletedPhase 2/3Johns Hopkins UniversityNCT00181142Written as Zenapax
- Daclizumab to Treat HIV-Infected PatientsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00080431Written as Daclizumab
- ANTI-TAC THERAPY FOR UVEITISCompletedPhase 1National Eye Institute (NEI)NCT00001526Written as Daclizumab (Zenapax)
- Daclizumab and Sirolimus to Treat UveitisCompletedPhase 1National Eye Institute (NEI)NCT00078689Written as Daclizumab
- Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00071838Written as Daclizumab
- Combination Daclizumab/Denileukin Diftitox to Treat UveitisCompletedPhase 2National Eye Institute (NEI)NCT00326508Written as Daclizumab
- Daclizumab to Treat Non-Infectious Sight-Threatening UveitisCompletedPhase 2National Eye Institute (NEI)NCT00070759Written as Daclizumab
- Islet Transplantation for Type 1 DiabetesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00014911Written as Daclizumab
See all 55 studies that test Daclizumab →
Given in every arm · 3 — Daclizumab is usual care beside what is tested
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) TransplantationCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00141037Written as Daclizumab
- Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant RecipientsCompletedPhase 3Hoffmann-La RocheNCT02686619Written as Daclizumab
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney TransplantWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00790439Written as Daclizumab
As the comparator · 1 — what is tested is compared with Daclizumab
Codes
What other systems call Daclizumab · ClinicalTrials.gg INT006756
- MeSH (NLM) D000077561DaclizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) CUJ2MVI71YDACLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 190353Confirmed FDA, Wikidata
- Wikidata Q412920daclizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1569DaclizumabOne source FDA
- DrugBank DB00111One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077561 | Daclizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | CUJ2MVI71Y | DACLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 190353 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412920 | daclizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1569 | Daclizumab | One source FDA |
| DrugBank | DB00111 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.